JAK-IN-23 is a dual inhibitor of JAK/STAT and NF-κB pathways with oral activity; it exhibits potent anti-inflammatory effects by reducing the release of various pro-inflammatory cytokines and can be used in the research of inflammatory bowel disease (IBD).